12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pandemrix regulatory update

EMA's CHMP said it has no new concerns related to the risk of narcolepsy in patients treated with GlaxoSmithKline's Pandemrix swine influenza A (H1N1) vaccine after reviewing preliminary results from the Finnish National Institute of Health and...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >